vs
Side-by-side financial comparison of Chemours Co (CC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $783.7M, roughly 1.7× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs -3.5%, a 16.5% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -2.1%). Chemours Co produced more free cash flow last quarter ($92.0M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
CC vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $783.7M |
| Net Profit | $-47.0M | $101.6M |
| Gross Margin | 11.7% | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | -3.5% | 13.0% |
| Revenue YoY | -2.1% | 31.2% |
| Net Profit YoY | -261.5% | 0.9% |
| EPS (diluted) | $-0.32 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $783.7M | ||
| Q3 25 | $1.5B | $706.3M | ||
| Q2 25 | $1.6B | $649.1M | ||
| Q1 25 | $1.4B | $569.0M | ||
| Q4 24 | $1.4B | $597.5M | ||
| Q3 24 | $1.5B | $543.9M | ||
| Q2 24 | $1.6B | $488.5M | ||
| Q1 24 | $1.4B | $441.7M |
| Q4 25 | $-47.0M | $101.6M | ||
| Q3 25 | $46.0M | $87.6M | ||
| Q2 25 | $-380.0M | $22.5M | ||
| Q1 25 | $-5.0M | $35.4M | ||
| Q4 24 | $-13.0M | $100.7M | ||
| Q3 24 | $-32.0M | $77.5M | ||
| Q2 24 | $60.0M | $188.6M | ||
| Q1 24 | $54.0M | $51.5M |
| Q4 25 | 11.7% | 72.6% | ||
| Q3 25 | 15.6% | 72.2% | ||
| Q2 25 | 17.2% | 69.7% | ||
| Q1 25 | 17.3% | 71.9% | ||
| Q4 24 | 19.4% | 72.1% | ||
| Q3 24 | 19.0% | 69.3% | ||
| Q2 24 | 19.8% | 67.7% | ||
| Q1 24 | 20.9% | 69.5% |
| Q4 25 | — | 18.7% | ||
| Q3 25 | 2.5% | 16.7% | ||
| Q2 25 | -15.4% | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | -0.1% | 18.3% | ||
| Q3 24 | -2.1% | 16.2% | ||
| Q2 24 | 4.4% | 11.2% | ||
| Q1 24 | 5.1% | 12.9% |
| Q4 25 | -3.5% | 13.0% | ||
| Q3 25 | 3.1% | 12.4% | ||
| Q2 25 | -23.5% | 3.5% | ||
| Q1 25 | -0.4% | 6.2% | ||
| Q4 24 | -1.0% | 16.9% | ||
| Q3 24 | -2.1% | 14.2% | ||
| Q2 24 | 3.9% | 38.6% | ||
| Q1 24 | 4.0% | 11.7% |
| Q4 25 | $-0.32 | $1.42 | ||
| Q3 25 | $0.31 | $1.24 | ||
| Q2 25 | $-2.53 | $0.32 | ||
| Q1 25 | $-0.03 | $0.50 | ||
| Q4 24 | $-0.07 | $1.38 | ||
| Q3 24 | $-0.22 | $1.08 | ||
| Q2 24 | $0.39 | $2.59 | ||
| Q1 24 | $0.36 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | — |
| Total DebtLower is stronger | $4.1B | $930.8M |
| Stockholders' EquityBook value | $250.0M | $1.5B |
| Total Assets | $7.4B | $3.2B |
| Debt / EquityLower = less leverage | 16.40× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | — | ||
| Q3 25 | $613.0M | — | ||
| Q2 25 | $502.0M | — | ||
| Q1 25 | $464.0M | — | ||
| Q4 24 | $713.0M | — | ||
| Q3 24 | $596.0M | — | ||
| Q2 24 | $604.0M | — | ||
| Q1 24 | $746.0M | — |
| Q4 25 | $4.1B | $930.8M | ||
| Q3 25 | $4.1B | $934.9M | ||
| Q2 25 | $4.1B | $939.0M | ||
| Q1 25 | $4.1B | $1.6B | ||
| Q4 24 | $4.1B | $1.3B | ||
| Q3 24 | $4.0B | $1.4B | ||
| Q2 24 | $4.0B | $1.4B | ||
| Q1 24 | $4.0B | $1.4B |
| Q4 25 | $250.0M | $1.5B | ||
| Q3 25 | $274.0M | $1.4B | ||
| Q2 25 | $228.0M | $1.5B | ||
| Q1 25 | $566.0M | $1.3B | ||
| Q4 24 | $571.0M | $1.2B | ||
| Q3 24 | $643.0M | $1.1B | ||
| Q2 24 | $714.0M | $998.4M | ||
| Q1 24 | $753.0M | $790.7M |
| Q4 25 | $7.4B | $3.2B | ||
| Q3 25 | $7.5B | $3.0B | ||
| Q2 25 | $7.5B | $3.5B | ||
| Q1 25 | $7.4B | $3.5B | ||
| Q4 24 | $7.5B | $3.1B | ||
| Q3 24 | $7.5B | $3.0B | ||
| Q2 24 | $7.2B | $2.9B | ||
| Q1 24 | $8.0B | $2.6B |
| Q4 25 | 16.40× | 0.61× | ||
| Q3 25 | 14.96× | 0.68× | ||
| Q2 25 | 17.99× | 0.64× | ||
| Q1 25 | 7.18× | 1.21× | ||
| Q4 24 | 7.11× | 1.07× | ||
| Q3 24 | 6.20× | 1.21× | ||
| Q2 24 | 5.53× | 1.36× | ||
| Q1 24 | 5.27× | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $183.3M |
| Free Cash FlowOCF − Capex | $92.0M | $48.2M |
| FCF MarginFCF / Revenue | 6.9% | 6.2% |
| Capex IntensityCapex / Revenue | 3.4% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $183.3M | ||
| Q3 25 | $146.0M | $125.7M | ||
| Q2 25 | $93.0M | $196.5M | ||
| Q1 25 | $-112.0M | $63.8M | ||
| Q4 24 | $138.0M | $147.7M | ||
| Q3 24 | $139.0M | $98.5M | ||
| Q2 24 | $-620.0M | $96.5M | ||
| Q1 24 | $-290.0M | $87.6M |
| Q4 25 | $92.0M | $48.2M | ||
| Q3 25 | $105.0M | $100.1M | ||
| Q2 25 | $50.0M | $177.9M | ||
| Q1 25 | $-196.0M | $51.5M | ||
| Q4 24 | $29.0M | $94.1M | ||
| Q3 24 | $63.0M | $71.8M | ||
| Q2 24 | $-693.0M | $74.0M | ||
| Q1 24 | $-392.0M | $65.5M |
| Q4 25 | 6.9% | 6.2% | ||
| Q3 25 | 7.0% | 14.2% | ||
| Q2 25 | 3.1% | 27.4% | ||
| Q1 25 | -14.3% | 9.1% | ||
| Q4 24 | 2.1% | 15.7% | ||
| Q3 24 | 4.2% | 13.2% | ||
| Q2 24 | -44.6% | 15.1% | ||
| Q1 24 | -28.8% | 14.8% |
| Q4 25 | 3.4% | 17.2% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 2.7% | 2.9% | ||
| Q1 25 | 6.1% | 2.2% | ||
| Q4 24 | 8.0% | 9.0% | ||
| Q3 24 | 5.0% | 4.9% | ||
| Q2 24 | 4.7% | 4.6% | ||
| Q1 24 | 7.5% | 5.0% |
| Q4 25 | — | 1.80× | ||
| Q3 25 | 3.17× | 1.43× | ||
| Q2 25 | — | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -10.33× | 0.51× | ||
| Q1 24 | -5.37× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
